Adenocarcinomas with a colorectal immunophenotype (CK7 -, CK20 +, CDX2 +) fall into this category, and these patients are recommended to receive site-directed therapy targeting the suspected primary origin for better outcomes. The gene discussed is CDX2; the disease is adenocarcinoma.